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Abstract: Pancreatic ductal adenocarcinoma (PDA) is a lethal disease and is one of the cancers 
that is most resistant to traditional therapies. Historically, neither chemotherapy nor radiotherapy 
has provided any significant increase in the survival of patients with PDA. Despite intensive 
efforts, any attempts to improve the survival in the past 15 years have failed. This holds true even 
after the introduction of molecularly targeted agents, chosen on the basis of their involvement in 
pathways that are considered to be important in PDA development and progression. Recently, 
however, FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) treatment has 
provided a limited survival advantage in patients with advanced PDA. Therefore, effective 
therapeutic strategies are urgently needed to improve the survival rate of patients with PDA. 
Results from the last 10 years of research in the field of PDA have helped to identify new 
immunological targets and develop new vaccines that are capable of stimulating an immune 
response. In addition, the information obtained about the role of the tumor microenvironment in 
suppressing the immune response and the possibility of targeting PDA microenvironment to limit 
immune suppression and enhance the response of effector T-cells has opened new avenues for 
treating this incurable disease. The time is ripe for developing new therapeutic approaches that 
are able to effectively counteract the progression and spreading of PDA. This review discusses 
the potential prospects in the care of patients with pancreatic cancer through vaccination and 
its combination therapy with surgery, chemotherapy, targeting of the tumor microenvironment, 
and inhibition of immunological checkpoints.
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Pancreatic cancer
Although lung, breast, prostate, and colorectal cancers are considered to be the “big 
four” cancer types in the USA, pancreas and liver cancers are expected to surpass 
breast, prostate, and colorectal cancers to become the second and third leading causes 
of cancer-related deaths by 2030, respectively.1 Pancreatic ductal adenocarcinomas 
(PDAs) arise from the exocrine pancreas and account for 95% of pancreatic cancers.2 
In the USA, there were an estimated 48,960 cases of new-onset pancreatic cancer in 
2015, which led to 40,560 deaths, with a 5-year survival rate of ∼7%.3 PDA is nearly 
universally lethal; ,20% of patients are suitable candidates for surgery at the time of 
diagnosis, and the median survival rate is 3.5 months and 12.6 months for  nonresected 
patients and resected patients, respectively.2,4 PDA evolves from noninvasive  precursor 
lesions that do not invade the basement membrane.5–7 Three precursors have been 
characterized, namely, pancreatic intraepithelial neoplasias (PanINs), intraductal 
papillary mucinous neoplasms, and mucinous cystic neoplasms.8
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The most frequent genetic abnormalities in PDA are 
mutational activation of the KRAS oncogene, inactivation of 
tumor suppressor genes, including CDKN2A, TP53, SMAD4, 
and BRCA2,9 widespread chromosomal losses, gene ampli-
fications,10 and telomere shortening.11
The early stages of pancreatic cancer are usually asymp-
tomatic, and therefore, most patients with PDA present an 
advanced-stage disease at diagnosis.12 Currently, no early 
detection tests are available, and as a result, most patients 
(80%–85%) are not diagnosed until the later stage of the 
disease.13–15 For the diagnosis of PDA, there are many poten-
tial serum biomarkers that allow stratifying patients according 
to the prognosis and for monitoring the therapy.16 CA 19-9 
is the only biomarker with clinical usefulness in predicting 
the patient’s response to chemotherapy,17,18  preoperative 
prognosis, as well as assessing treatment response, overall 
survival, and recurrence.19–23 However, CA 19-9 has several 
limitations; it is not a specific biomarker for PDA and may 
also be elevated in cholestasis. In addition, patients who are 
negative for Lewis antigen A or B (∼10% of patients with 
PDA) do not synthesize CA 19-9 and have undetectable 
levels, even in the advanced stages of the disease.24
A promising discovery of biomarkers for the early diag-
nosis of PDA came from a serological proteome approach, 
which identified autoantibodies as a potential diagnostic 
marker in patients with PDA, in a genetically engineered 
mouse (GEM) model of PDA and in a prediagnostic cohort. 
These autoantibodies recognize the cytoskeletal protein 
Ezrin25 and the phosphorylated α-enolase (ENO1), a gly-
colytic enzyme, which also functions as a plasminogen 
receptor.26 Combined detection of antibodies to Ezrin, phos-
phorylated ENO1, and CA 19-9 correctly discriminates PDA 
from control patients with high sensitivity and specificity.25 
A cell surface proteoglycan, glypican-1, specifically enriched 
on PDA cell-derived exosomes, was found to be able to 
discriminate early stages of pancreatic cancer.27 Validating 
these newly discovered markers in large cohorts of early 
and advanced patients with PDA, as well as in selected risk 
populations, and developing easy and convenient clinical tests 
for their detection will greatly facilitate curative surgical and 
immune-based therapies.
Conventional therapies
Currently, surgical resection offers the only hope of cura-
tive therapy for PDA. Nevertheless, this procedure is only 
considered in patients with resectable PDA, which represents 
∼20% of patients.28,29 Although additional palliative care is 
often utilized, controversy surrounds the potential benefits. 
Several poor predictors for successful resection have been 
identified, including lymph node involvement,30 high tumor 
grade,31 large tumor size,32 elevated CA 19-9 levels,32 and 
positive margins of tumors following resection.33 These same 
factors are also indicative of recurrence of pancreatic tumors. 
Even with complete and successful surgical resection, 5-year 
survival rates remain dismal, at ∼20% following surgery.34 
Therefore, postoperative chemotherapy involving gemcit-
abine or 5-fluorouracil or chemoradiation is almost always 
incorporated into the therapeutic regimen. Developing 
other complementary agents to enhance chemotherapeutic 
effects such as Hedgehog signaling inhibitors,35 second 
mitochondria-derived activator of caspase mimetics,36 
microRNAs,37 resveratrol,38 capecitabine,39 thymoquinone,40 
heat-shock protein complements,41 or curcumin42 are 
currently under review.13 Certain patients might receive 
neoadjuvant (preoperative) gemcitabine-based therapy that 
increased survival rates.43,44 Chemotherapy with radiation has 
also been shown to improve survival, but not stage, of locally 
invasive tumor patients without metastasis.45
Due to the difficulties of making an early diagnosis, most 
patients present metastatic PDA upon initial diagnosis. In the 
advanced stage of disease, PDA causes imminent mortality. 
Gemcitabine was once considered as the chemotherapeutic 
standard of care for advanced PDA, which improved median 
overall survival as well as 1-year survival (18%).46 At present, 
FOLFIRINOX (5-fluorouracil,  leucovorin, irinotecan, and 
oxaliplatin) is considered as the new standard in the treat-
ment of advanced PDA.47 Compared to gemcitabine alone, 
FOLFIRINOX has been shown to result in a better objective 
response rate (32% vs 9%), improved median progression-
free survival (6.4 months vs 3.3 months), and increased 
overall survival (11.1 months vs 6.8 months). While the 
toxicity levels associated with FOLFIRINOX are greater 
than those caused by gemcitabine, the effects did not have 
a significant impact on the quality of life, and very few 
deaths correlated with toxicity have been reported. However, 
gemcitabine-based therapies in patients who do not tolerate 
FOLFIRINOX as a first-line therapy have been demonstrated 
to be beneficial.47
In the recent years, targeted therapies have been tested 
in metastatic pancreatic cancer patients: Erlotinib, an inhibi-
tor of the epidermal growth factor receptor (EGFR) which, 
in combination with gemcitabine, significantly decreased 
tumor progression and increased overall survival rates.48 
This was especially true in patients with EGFR mutations 
compared to wild-type EGFR (ClinicalTrials.gov number, 
NCT01608841).49
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In addition, nab-paclitaxel (microparticles of albumin-
containing paclitaxel that diminishes the stromal tissue 
associated with PDA)50,51 in combination with gemcitabine 
improved the overall and progression-free survival, as well 
as the response rate in patients with metastatic PDA.52
Mechanisms and major players 
of suppression of the immune 
response in PDA
Tumors engage the immune system response from their 
inception and this initially involves mainly macrophages 
and mast cells. However, even early on, the engagement of 
T-cells is evident.53 Immune cells (principally innate cells) 
are able to recognize tumor cells as “different” and fight them 
by inducing an inflammatory response. However, inflamma-
tion creates a tumor mutagenic environment, either directly 
through free radical generation or indirectly via alterations in 
the microbiome and barrier functions, which enable access 
of genotoxic bacteria to the epithelial cells.54
Inflammation can promote the formation of premalignant 
lesions and accelerate the PDA development. Indeed, PDA 
is characterized by an immunosuppressive environment, 
which favors tumor progression and invasion. Pancreatitis, or 
inflammation of the pancreas, often leads to pancreatic dam-
age and promotes the development of neoplastic disease.
In a GEM model that spontaneously develops PDA 
comparable to the human disease, 50% of the tumor was 
composed of leukocytes, particularly immunosuppressive 
cells, including tumor-associated macrophages (TAM), 
myeloid-derived suppressor cells (MDSCs), and regulatory 
T-cells (Tregs), as well as a small percentage of effector 
T-cells. At early stages of carcinogenesis, for example, 
 during PanIN development, Tregs and MDSC dominate the 
tumor infiltrate. Upon disease progression to PDA, CD4+ and 
CD8+ T-cells are inconsistently found to be associated with 
the tumor, and these CD8+ T-cells associated with the tumor 
appear to be inactivated, suggesting a suppressed immune 
environment.55 In all stages of the disease, there is a strong 
inverse correlation between MDSC and CD8+ T-cells, sug-
gesting that MDSCs are the mediators of the immunosup-
pression.55 Other preclinical models have demonstrated the 
role of chronic inflammation in PDA progression56 and of 
infiltrating neutrophils in mutant Kras-driven tumorigenesis 
and evasion from the immune system by promoting early 
angiogenesis.57,58
Many studies have reported that targeting specific tumor 
microenvironment components (Table 1), especially in con-
junction with chemotherapy, unleashes the T-cell response 
against PDA. Altering the tumor stroma with an anti-CD40 
agonist, which activated macrophages, showed therapeutical 
efficacy both in human and mouse PDA. The therapeutic 
effect of anti-CD40-dependent macrophage activation does 
not require CD4+ and CD8+ T-cells.59 However, when the anti-
CD40 agonist and gemcitabine treatment are combined with 
clodronate-encapsulated liposomes that deplete macrophages, 
a T-cell-dependent regression of the subcutaneous tumor is 
elicited in GEM.60 Ly6ClowF4/80+ macrophages appear to be 
responsible for this effect, and they reside outside the tumor 
microenvironment but are able to inhibit the infiltration of 
CD4+ and CD8+ T-cells into the tumor site, creating a site 
of acquired T-cell “immune privilege” in PDA. These data 
demonstrate that a T-cell response capable of inducing tumor 
regression can be invoked against spontaneously arising PDA 
and indicate a strategy that  targets macrophages for enhanc-
ing the efficacy of T-cell-based immunotherapy in PDA. In 
a similar manner, the depletion of TAM by inhibitors of the 
Table 1 Strategies to modulate tumor microenvironment
Target Models Strategies References
CD40 Preclinical and clinical (both PDA) Agonist monoclonal Ab to CD40 in  
combination with gemcitabine
59,110
CSF-1R Preclinical (glioma) and clinical (breast ca) Monoclonal Ab to CSF-1R (BLZ945) 65
CCR2 Preclinical (breast) Monoclonal Ab to CCL2 62,63
GM-CSF Preclinical (transplantable PDA) Short hairpin RNA for GM-CSF  
or monoclonal Ab to GM-CSF
66,68
Monocytes Preclinical (fibrosarcoma, ovarian,  
Lewis lung ca)
Trabectedin 111
Ly6G Preclinical (PDA) Monoclonal Ab to Ly6G (1A8) 67
CXCL12 Preclinical (PDA) Monoclonal Ab to CXCL4 (AMD3100) 70
Smoothened Preclinical and clinical (PDA) iPi-926, semisynthetic derivative  
of cyclopamine, and genetic ablation
71,73
α-SMA Preclinical (PDA) Genetical ablation of α-SMA+ cells 72
Abbreviations: PDA, pancreatic ductal adenocarcinoma; RNA, ribonucleic acid; GM-CSF, granulocyte and monocyte-colony stimulating factor; Ab, antibody; ca, cancer; 
α-SMA, alpha-smooth muscle actin.
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chemokine receptor CCR2 or the colony stimulating factor 
1 receptor, in conjunction with gemcitabine, enhanced the 
infiltration of CD4+ and CD8+ T-cells, reduced the number of 
Treg cells, and inhibited the growth and spreading of GEM-
derived PDA cells orthotopically injected into syngeneic 
mice.61–63 Notably, the blockade of colony stimulating factor 1 
(CSF1) or CSF1 receptor (CSF1R) significantly enhanced the 
responses to immune checkpoint-based immunotherapy.64,65 
Similar results were obtained by the depletion of myeloid 
cells, which were actively recruited and maintained by two 
cytokines, namely, granulocyte-colony stimulating factor 
and granulocyte and monocyte–colony stimulating factor 
(GM-CSF), principally secreted by PDA cells harboring Kras 
mutations.66–68 Therefore, targeting the TAM or macrophages 
that are responsible for inhibiting the T-cell immune response 
is a feasible option effective, especially in combination with 
chemotherapy, for treating PDA. A well-known feature of 
PDA is the rapid development of desmoplasia, which is 
derived from pancreatic stellate cells that are activated to pro-
liferate and produce collagens, laminin, and fibronectin, that 
differentially shape the stroma.69 The stroma also contributes 
to tumor hypoperfusion and hypoxia and harbors suppressive 
infiltrative macrophages and inflammatory cells. Therefore, 
limiting either the inflammatory response or the stroma deple-
tion could enhance drug delivery to the cancer cells within 
the tumor mass while disrupting deleterious stroma–cancer 
cell interactions. A lot of data seem to support this hypoth-
esis, for example, ablation of cancer-associated fibroblasts or 
inhibition of cancer-associated fibroblasts-secreted CXCL12 
chemokines led to a T-cell infiltration of the tumor site and 
synergized with other immunotherapeutic strategies to greatly 
diminish cancer cells.70,71 New insights have been revealed 
from two studies that have demonstrated that 1) the stroma 
in PDA is protective, and this action is already exerted at the 
PanIN stage and72 2) targeting the stroma not only can lead 
to a more aggressive and proliferating form of PDA cells, 
but also can “prime” the tumor to more efficiently respond to 
immune checkpoint blockade and to antiangiogenic therapy;73 
therefore, it is important to reassess various therapeutic 
approaches bearing in mind that the actions of the stroma in 
PDA may be context dependent.74
All these data have corroborated the original idea that 
PDA is poorly immunogenic or an “immune privileged” site. 
However, the presence of T-cells in PDA and their ability 
to be activated by tumor antigens have been documented. 
Higher levels of tumor-infiltrating CD4+ and CD8+ cells and 
dendritic cells (DCs) positively correlate with longer survival 
after surgical resection.75 Indeed, clinically, CD8+-cells 
are elevated in the circulation of patients with PDA,76 and 
leukocytes, the majority of which are T-cells, surround the 
pancreatic lesion.77 T-cells are more frequently found in the 
fibrotic interstitial tissue than in the epithelial area of PDA.78 
Notably, PDA-infiltrating lymphocytes specifically recognize 
PDA-associated antigens but are often frustrated in their 
effector functions by the presence of Tregs.79
Vaccination in PDA
The prospect of effective immunotherapies for patients with 
PDA is now becoming a clinical reality, and the iden tification 
of tumor-associated antigens has been crucial in creating a 
springboard to accelerate this reality. The US FDA approval 
of PROVENGE (Sipuleucel-T), an autologous cellular 
vaccine, in 2010, as well as the anticytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) monoclonal antibody (mAB) 
ipilimumab in 2011, represents the success and great potential 
of immuno therapy in treating cancers.
The idea of training the immune system in vivo to 
 recognize and kill cancer cells is the basis of the hypothesis 
for using vaccines in patients with cancer. In addition, any 
lessons from antiviral immune responses and vaccinations 
against infectious disease have been useful to develop 
antitumor vaccines. Types of immunotherapy that are cur-
rently being tested in clinical trials for PDA include whole 
cell, peptide/DNA, antigen pulsed-DC vaccines, and mAb 
treatments.
whole-cancer cell vaccines
Cancer vaccines are preparations aimed at boosting the 
patient’s immune system against the administered antigen, 
which is usually specific for a particular tumor type, in order 
to protect the patient. There are several ways to deliver 
vaccines: whole-cell recombinant vaccines, DC vaccines 
that combine antigens with DC to present to leukocytes, 
DNA vaccines that act by inserting viral or bacterial DNA 
into animal or human cells, or peptide vaccines to modulate 
T-cell immunity.
Whole-cell vaccines typically use irradiated PDA cells 
as immunogens. These cells have the potential to elicit a 
robust immune response because they express the full rep-
ertoire of tumor-associated antigens. Algenpantucel-L is 
one of the most clinically advanced and promising immuno-
therapies; it is an irradiated, live combination of two human 
allogeneic PDA cell lines that express the murine enzyme 
α-1,3-galactosyl transferase, which directs the synthesis 
of α-galactosyl epitopes, usually absent in humans and, 
therefore, has the potential to be strongly recognized by 
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the immune system. Algenpantucel-L causes a hyperacute 
rejection of such allografts in humans, which is thought to 
trigger an immune response against cancer cells.80 A multi-
center Phase II trial (NLG0205) (ClinicalTrials.gov identifier: 
NCT00569387) of algenpantucel-L combined with adjuvant 
chemotherapy using gemcitabine and 5-fluorouracil/radiation 
after resection showed the induction of eosinophilia for up to 
2 years; 62% of patients were disease free after 1 year, with 
a 1 year overall survival rate of 86% (vs 69% of patients 
who received the same chemoradiation regimen without 
the vaccine).81 Another whole-cell vaccine is GVAX, which 
consists of irradiated tumor cells expressing the murine GM-
CSF. This caused a potent, long-lasting antitumor response 
requiring both CD4+ and CD8+ T-cells in the melanoma 
system.82 Phase I83 and single-institution Phase II84 clinical 
trials have also shown promising results for patients with 
PDA, even if only surgically treated patients were enrolled. 
Further stage II/III investigations are needed in patients with 
advanced or metastatic disease, and current clinical trials will 
provide important information (ClinicalTrials.gov identifier: 
NCT01088789, NCT01417000, NCT00727441).
Peptide vaccines and adoptive  
transfer therapy
The first peptide vaccine applied to PDA in a clinical trial 
was the synthetic Ras-peptide vaccine, which was proven 
to be safe.85 Combination with GM-CSF induced a spe-
cific immune response in 25 out of 43 patients and those 
with advanced cancer and immune response to the vaccine 
showed prolonged survival compared to nonresponders.86 
Other peptide vaccines investigated in clinical trials with 
PDA patients include the telomerase peptide vaccine 
(GV1001), the carcinoembryonic antigen (CEA), alone or 
in combination with mucin-1 (MUC-1), and survivin, in a 
case report of a 77-year-old patient with metastatic PDA 
refractory to gemcitabine.87 A study was conducted to 
investigate the safety and immunogenicity in patients with 
nonresectable pancreatic carcinoma using GV1001 for vac-
cination in combination with GM-CSF and gemcitabine as 
a first-line treatment. Mild adverse events were observed, 
and a GV1001-specific immune response, albeit transient, 
was reported in 75% of patients who contextually received 
GV1001, GM-CSF, and gemcitabine.88 The multicenter 
Phase III trial of the GV1001 vaccine in advanced and meta-
static PDA recruited 1,062 patients in 52 centers throughout 
the UK. There was no significant difference in the overall 
survival between the groups that received the vaccine and 
the control group receiving chemotherapy, but two biomark-
ers that defined responders to the vaccine were identified.89 
A viral-based vaccine was used to target the CEA antigen 
in combination with a poxvirus-based vaccine containing 
three T-cell costimulatory molecules such as B7-1 (CD80), 
intracellular adhesion molecule 1, and leukocyte function 
associated antigen-3. Phase I trials have demonstrated that 
CEA-T-cell costimulatory molecules vaccine is safe, is able 
to generate a significant anti-CEA immune response, and 
has some clinical benefit in patients with advanced cancer.90 
The addition of MUC-1 and of a boost with a different 
viral-expressing vaccine (PANVAC-V and vaccinia virus 
to immunize and PANCAV-F and fowl-pox virus to boost) 
in combination with GM-CSF showed an induction of anti-
bodies in some patients, with a consequent clinical  benefit. 
However, a Phase III trial failed to improve the overall 
survival compared to the canonical chemotherapy.91 CEA and 
MUC-1 antigens were also used to pulse DC purified from 
patients and reinfused after in vitro expansion and loading. 
Both these DC-based vaccines were demonstrated to be safe, 
well tolerated, and elicited remarkable T-cell responses.92,93 
To our knowledge, no major trials have been carried out 
or are ongoing; thus, both strategies would require further 
investigations to translate into clinical efficacy. MUC-1 RNA 
was also used to transfect autologously purified DC, which 
were intradermally injected into unresectable or recurrent 
patients with PDA, who also received gemcitabine and 
in vitro expanded cytotoxic T-cells in the presence of a PDA 
cell line plus IL-2. The median survival rate was 13.9 months 
and the 1 year survival rate was 51.1%, with a disease control 
ratio of 61.9%. Liver metastasis occurred in just five patients 
of the 35 patients investigated with no liver metastasis before 
treatment, and there were no severe toxicities associated with 
the adoptive immunotherapy.94
Adoptive T-cell therapy, which aims at in vitro expan-
sion and “education” of T-cells from patients with cancer, 
for subsequent reinfusion to fight cancer cells in vivo, has 
not been widely explored in PDA. One Phase I  clinical trial 
( ClinicalTrials.gov identifier: NCT02465983) is recruit-
ing patients and involves the transfection of patient T-cells 
with a specific receptor recognizing a mesothelin peptide 
(CART-meso) and the protein CD19 (CART-19) expressed by 
B-cells. The  latter T-cells should kill patient B-lymphocytes 
by preventing the production of antibodies against CART-
meso cells.  Mesothelin is an antigen that has been initially 
 characterized in ovarian cancer and PDA95 and has been 
observed to induce the CD8+ T-cell response in patients 
treated with GVAX and cyclophosphamide, either with or 
without live attenuated-Listeria monocytogene-expressing 
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mesothelin.96 In this study, the prime/boost strategy with 
GVAX and L. monocytogene-expressing mesothelin 
extended survival of patients with pancreatic cancer and 
enhanced mesothelin-specific CD8+ T-cell responses and 
was associated with a longer overall survival, regardless of 
the treated arm.97
Wilms tumor (WT-1) peptide-based vaccine in combi-
nation with gemcitabine is another strategy that was shown 
to be well tolerated in unresectable patients with advanced 
PDA. The Phase I clinical trial demonstrated its safety and 
revealed a statistically significant correlation between longer 
survival and positive delayed-type hypersensitivity to WT-1. 
Moreover, longer survivors displayed a higher frequency of 
memory WT-1-specific cytotoxic T-cells both before and 
after treatment.98
Cancer testis (CT) antigens were the first tumor- associated 
antigens proposed for antitumor vaccination strategies 
because of their specific expression in tumors but not normal 
cells of different histological origin. Several preclinical and 
clinical studies demonstrated CT-based immunotherapies as 
being effective in inducing a specific immune response and 
occasionally clinical responses in different types of tumors.99 
A peptide vaccine consisting of four distinct nonamers 
from CT and vascular endothelial growth factor receptor 1 
(VEGF-R1) and 2 (VEGF-R2) proteins has been shown to 
be well tolerated and able to elicit a peptide-specific T-cell 
response in all the nine patients with advanced PDA refrac-
tory to standard chemotherapy enrolled in a Phase I clinical 
trial. Notably, clinical benefits were observed in four out of 
nine patients, with a disease-free period of 90 days and an 
overall survival of 207 days.100
Passive immunotherapy combined  
with antitumor vaccines
Several preclinical studies are in the process of investigating 
the potential of Treg suppression and immune  checkpoint 
blockade by mAbs alone or in combination with chemo-
therapy to boost the patient’s immune system in recogniz-
ing and destroying tumors. Administering ipilimumab in 
combination with the GVAX vaccine (ClinicalTrials.gov 
 identifier: NCT00836407) and the administration of niv-
olumab in combination with the GVAX vaccine and cyclo-
phosphamide (ClinicalTrials.gov identifier: NCT02451982) 
are two representative clinical trials.  Ipilimumab and 
nivolumab are mAb against CTLA-4 and programmed cell 
death-1 (PD-1), respectively. Both molecules are protein 
receptors expressed on the surface of activated T-cells and 
are known as checkpoints due to their inhibitory function. 
After  binding of CTLA-4 with the costimulatory molecule 
CD80 and of PD-1 with the ligand PD-L1, an inhibitory 
signal to T-lymphocytes is  transmitted. The success obtained 
in autoimmune disease with the anti-CTLA-4 antibody treat-
ment has prompted scientists to also employ this antibody in 
patients with cancer. The notion of blocking the inhibitory 
signal in order to sustain the antitumor T-cell response for 
longer was straight forward and insightful, and it has been 
demonstrated to be effective in potentiating the antitumor 
response and in unrestrained T-cell proliferation in different 
types of cancer. In a first small study (30 patients with PDA 
previously treated), the combination of ipilimumab with the 
GVAX vaccine showed a potential  clinical benefit, which 
needs to be confirmed in a larger cohort. Among the patients 
with increased overall survival, there was an increase in the 
peak of mesothelin-specific T-lymphocytes and an enhance-
ment of the T-cell repertoire.101 Although not without side 
effects, the blockade of checkpoint molecules displays a 
great therapeutical potential.
In conclusion, researchers have long considered PDA 
as being nonamenable to immunotherapy, owing to an 
immunosuppressive tumor microenvironment. However, 
preclinical and clinical studies have shown the reestablishing 
of tumor immunosurveillance by activating T-cells and 
macrophages, and several clinical trials are following this 
direction (Table 2).
Novel DNA vaccine promising  
strategy for PDA therapy
Among vaccines, DNA vaccines display several advantages 
such as they are stable, do not contain viral proteins that 
could downregulate the immune system or elicit neutraliz-
ing antibodies, and are safe, as several studies have shown 
that mutations arising from a putative integration event are 
extremely rare.102 In turn, DNA vaccination usually fails to 
mount a strong immune response and requires additional 
adjuvant strategies.
For several years, our group has focused on the identifi-
cation of novel PDA-associated targets to use for developing 
immunotherapeutic strategies to be applied in treating this 
dismal disease. Through a serological approach, we have 
identified 12 PDA-associated proteins,103 which we have 
investigated for their ability to activate a T-cell immune 
response both in vitro and in vivo. Among these, ENO1 
has been shown to be a promising candidate target as it 
was recognized by the autoantibodies present in .60% of 
patients with PDA.26,104 ENO1 is coded by the ENO1 gene 
and is overexpressed in the cytoplasm of PDA cells being 
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Table 2 Clinical trials consisting in vaccine strategiesa
Number Status Intervention Phase
NCT00836407 Completed Allogeneic PDA cells transfected with GM-CSF + ipilimumab i
NCT01088789 Recruiting Allogeneic PDA cells transfected with GM-CSF given long term ± 
cyclophosphamide
ii
NCT01896869 Recruiting Allogeneic PDA cells transfected with GM-CSF + ipilimumab  
in patients receiving FOLFiRiNOX
ii
NCT00727441 Active, not recruiting GvAX + cyclophosphamide NS
NCT00389610 Active, not recruiting GvAX after surgery ii
NCT00569387 
NCT00614601
Both completed Algenpantucel-L after surgery ii
NCT00305760 Completed GvAX + cituximab/cyclophosphamide ii
NCT02451982 Not yet recruiting GvAX + cyclophosphamide ± nivolumab i/ii
NCT00084383 Completed GvAX + chemotherapy after surgery ii
NCT01595321 Active, not recruiting Allogeneic PDA cells transfected with GM-CSF +  
cyclophosphamide + stereotactic body radiation + FOLFiRiNOX
i
NCT00683085 Terminated HLA-A02 restricted peptide from veGF-R + gemcitabine i/ii
NCT00425360 Completed GM-CSF + peptide from telomerase + capecitabine or gemcitabine iii
NCT00837135 withdrawn Gi-4000 (ras peptide containing different mutated sites) ±  
T-cell adoptive transfer
i
NCT00655785 Completed Peptides derived from veGF-R1 and R2 + gemcitabine i/ii
NCT00868114 Active, not recruiting KLH-pulsed autologous dendritic cell vaccine in combination  
with TNFerade or radiation
ii
NCT02465983 Recruiting CART antimesothelin + CART anti-CD19 i
Note: aFor complete review see ClinicalTrials.gov.
Abbreviations: PDA, pancreatic ductal adenocarcinoma; GM-CSF, granulocyte and monocyte-colony stimulating factor; FOLFiRiNOX, 5-fluorouracil, leucovorin, irinotecan, 
and oxaliplatin; NS, not specified; VEGF-R, vascular endothelial growth factor-receptor; KLH, keyhole limphet hemocyanin.
membrane expressed.104,105 In the cytoplasm, ENO1 acts as 
a glycolytic enzyme, whereas membrane-expressed ENO1 
behaves as a plasminogen receptor and plays an important 
role in the cell migration.106 The ENO1 antibody effectively 
inhibits the spreading and invasion of PDA in vivo and 
in vitro.105 Patients with PDA with autoantibodies to ENO1 
also present an ENO1-specific T-cell response, which is 
not observed in patients with no ENO1 autoantibodies.104 
Upon transfer into immunocompromised mice, ENO1-
specific T-cells inhibit the growth of xeno-transplanted 
human pancreatic tumors. Despite the ubiquitous presence 
of ENO1 in all mammalian cells, normal cells expressing 
low levels of ENO1 are spared by ENO1-specific cytotoxic 
T-lymphocytes.104 Anti-ENO1-specific T-cells were found to 
infiltrate tumor tissue in patient with resected PDA.79 These 
results led us to develop a DNA-based vaccine to assess the 
ability of an ENO1-specific antitumor response to inhibit 
the tumor growth. To do this, we exploited two of the most 
sophisticated murine models that spontaneously develop 
autochthonous PDA (known as KC and KPC mice). GEM 
that develops spontaneous PDA was vaccinated with a plas-
mid encoding human ENO1, which displays .95% identity 
(99% homology) with the mouse ortholog. The ENO1 DNA 
vaccine significantly induced a specific immune response 
that prolonged the survival of both PDA mouse models: 
from 336 days to 474 days of age for KC mice, the lon-
gest overall survival ever reported, and from 203 days to 
245 days for KPC mice. The ENO1 DNA vaccine elicited 
several protective immunological mechanisms, namely, 
high levels of anti-ENO1 IgG, activation of specific Th1 
and Th17 cells, and a large recruitment of CD3 cells into 
the tumor area. Notably, anti-ENO1 IgG was able to bind 
to the cell surface of murine PDA cells and induce their 
killing by complement-dependent cytotoxicity. Th1/Th17 
cytokines favor the switching to effector subclasses of anti-
ENO1  antibodies. An additional effect of the ENO1 DNA 
vaccine is the decrease in cells with suppressive  activity, 
typically found in the tumor microenvironment, namely, 
MDSC and Tregs. Of clinical relevance, the therapeutic 
efficacy of the ENO1 DNA vaccine was observed to be 
very  promising when the administration protocol started at 
8 months to 9 months of age.107 In these mice, the ENO1 
DNA vaccine also induced the formation of intratumoral 
tertiary lymphoid tissue (TLT) with active germinal centers 
and correlated with increased recruitment of T-cells.108 
Analysis of human PDA tissues by immunohistochemistry 
revealed two distinct patterns of B-cell distribution, either 
as randomly infiltrating cells (CD20-tumor-infiltrating 
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lymphocytes) or strategically located within organized TLT 
(CD20-TLT). Notably, high density of CD20-TLT correlated 
with CD8+ T-cell infiltration and a more favorable prognostic 
value.108 Overall, data on ENO1 vaccination indicate that it 
is a promising candidate target to design adjuvant therapies 
to prevent recurrences in resected patients or to prolong the 
survival of untreatable patients.
Conclusion
Despite several successes in curing solid tumors, PDA 
remains the only tumor to have had the same mortality rate 
for the last 15 years. To date, the only curative treatment is 
represented by surgical resection, only applicable, however, 
to a small percentage of patients. Recent advances have 
been raised with the use of gemcitabine in a neoadjuvant 
setting to increase the resectable percentage of patients with 
PDA (Figure 1). The time is ripe to transfer the information 
obtained to elicit an active immune response against PDA to 
clinical trials that effectively prolong the survival of patients 
with PDA. The right drug combination could transform 
encouraging vaccine preclinical and clinical results into 
an effective protocol able to cure PDA (Figure 1). A lot of 
evidence has shown that several anticancer agents, including 
classic chemotherapeutics and targeted compounds, stimu-
late tumor-specific immune responses either by inducing 
immunogenic cell death or by engaging immune effector 
mechanisms.109 Their combination with vaccination against 
selected immunological targets (eg, ENO1 and mesothelin) 
and with different strategies (whole cells, DC, peptides, 
or DNA) will allow the design of novel therapies to elicit 
effective immune responses in resected patients to prevent 
recurrences or to prolong survival of unresectable patients 
(Figure 1). In addition, the novel strategies for modulat-
ing the tumor microenvironment and immunosuppressive 
mechanisms through mAb may be combined to further 
enhance the antitumor response induced by vaccination 
following surgery, chemo- or radiotherapy (Figure 1). The 
greatest challenge in future studies will be to establish the 
most effective timeline and the best combinations of dif-
ferent treatments.
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